Background {#Sec1}
==========

The etiology of autoimmune diseases in general has remained a biomedical mystery. It is not clear how and why some molecules or tissue components of the body become a self-target of the immune defense system, whereas most do not. In previous studies, we demonstrated that certain molecules from dying cells have affinity to dermatan sulfate (DS), and that these molecules can form macromolecular complexes with DS to co-stimulate autoreactive CD5+ B cells to secrete autoantibodies \[[@CR1]\]. Furthermore, we demonstrated that molecules with affinity to DS have a high propensity to be autoantigens (autoAg) \[[@CR2]\]. We proposed a uniform principle of autoantigenicity that explains how a vast variety of seemingly unrelated molecules can become autoantigenic by means of a shared biochemical property. In this study, we sought to test this principle and to define the repertoire of possible autoantigens, i.e., the autoantigen-ome, in autoimmune liver diseases.

Autoimmune diseases of the liver occur when the body's own immune system attacks the liver \[[@CR3]--[@CR5]\]. These diseases have different clinical patterns with regard to degree of severity and clinical course, but they all share one important feature, i.e., the liver being the target of an aberrant autoimmune attack by autoantibodies and/or autoreactive cells. Autoimmune liver diseases are typically chronic conditions, and patients may experience persistent or recurrent autoimmune insults to the liver, often without overt symptoms. As the autoimmune attack persists, liver tissue scars and leads to hepatic fibrosis; and as fibrosis progresses to cirrhosis, liver function is compromised. Ultimately, end-stage liver disease and liver failure may ensue, requiring organ transplantation.

Among autoimmune diseases of the liver, autoimmune hepatitis (AIH) \[[@CR3]\], primary biliary cirrhosis (PBC) \[[@CR4]\], and primary sclerosing cholangitis (PSC) \[[@CR5]\] are the most prominent. In AIH, the immune system attacks the hepatocytes and causes chronic inflammation of the liver. About 70% of AIH patients are female. In PBC, the autoimmune reaction is directed at small biliary ducts inside the liver. In PSC, autoimmunity targets the larger extrahepatic bile ducts. Characteristic morphological patterns are chronic inflammation and a hepatic pattern of injury with prominent plasma cells in AIH, destruction of small intrahepatic bile ducts and canals of Hering in PBC, and periductal fibrosis and inflammation of the larger bile ducts, often along with inflammatory bowel disease, in PSC. Although most liver autoimmune diseases fall into these three categories, overlaps and other syndromes also occur.

Autoimmune liver diseases are typically associated with several classes of autoantibodies, including ANA, AMA, anti-SMA/anti-F-actin, anti-LKM, and others \[[@CR6], [@CR7]\]. For AIH and PBC, testing for liver-related autoantibodies is a prerequisite for diagnosis. For PSC, autoantibodies are frequently present but their diagnostic value has not been established. When diagnosed at an early stage, autoimmune hepatitis can be controlled by daily doses of steroids and other medicines that suppress inflammation. However, these treatments only suppress or slow down the overactive immune system, but cannot cure the disease. Understanding the molecular origins of autoimmune liver diseases is therefore crucial to finding more effective therapies.

Methods {#Sec2}
=======

DS-Sepharose resin synthesis {#Sec3}
----------------------------

DS-Sepharose resins were prepared by coupling dermatan sulfate (DS; Sigma-Aldrich) to EAH Sepharose 4B resins (GE Healthcare). Sepharose resins (20 ml) were washed with distilled water and 0.5 M NaCl and then mixed with 100 mg of DS dissolved in 10 ml of 0.1 M MES buffer (pH 5.0). N-ethyl-N-(3-dimethylaminopropyl) carbodiimide hydrochloride (Sigma-Aldrich) was added to a final concentration of 0.1 M. The reaction proceeded at 25 °C for 24 h with end-over-end rotation. After the first 60 min, the pH of the reaction mixture was readjusted to 5.0. After the coupling, the resins were washed three times, each time with a low pH buffer (0.1 M acetate, 0.5 M NaCl, pH 5.0) and a high pH buffer (0.1 M Tris, 0.5 M NaCl, pH 8.0). The washed DS-Sepharose resins were suspended in 10 mM phosphate buffer (pH 7.4) and packed into a C16/20 column (GE Healthcare). The column was equilibrated with 10 mM phosphate buffer before use.

Mouse liver protein extraction {#Sec4}
------------------------------

Livers were obtained from 5-month-old BALB/cJ female mice (Jackson Laboratory, Bar Harbor, Maine). The mouse tissue use was approved by the Institutional Animal Care and Use Committee (IACUC) of Brigham and Women's Hospital (Boston, MA). All animal care was provided according to institutional, local, state, and federal regulations at the Brigham and Women's Hospital research animal facility. A total of 20 mice were killed with CO~2~, their blood was removed through heart puncture, and their livers were collected immediately. Livers were cleaned by rinsing with phosphate buffered saline (PBS, pH 7.2) twice and then stored at 4 °C for 1 h, -20 °C for 2 h, and then -80 °C until further processing. Thawed livers were cut to small pieces and pressed through a cell strainer (Fisher Scientific). To remove red blood cells, the liver tissue was mixed with 10 ml of RBC (red blood cell) lysis buffer for 10 s. After centrifugation for 5 min, the supernatant was discarded. The liver tissue was mixed with 40 ml of RIPA lysis buffer (Sigma-Aldrich) and 4 tablets of protease inhibitor (cOmplete protease inhibitor cocktail, Sigma-Aldrich). The tissue mixture was sonicated for 10 min or until all tissue pieces appeared dissolved. The mixture was centrifuged at 13,300 rpm for 20 min, and the supernatant that contains total soluble liver proteins was collected. Protein concentration was measured by the RC DC protein assay (Bio-Rad).

DS-affinity fractionation {#Sec5}
-------------------------

Pilot affinity fractionations were performed in small centrifuge tubes. Aliquots of 2 ml resin were centrifuged to remove the storage buffer, and 0.5 ml of extracted liver proteins was added. The tube was mixed by rotating end-over-end at room temperature for 1 h to allow sufficient binding of proteins to DS-resin. The resin slush was centrifuged, and the supernatant containing unbound proteins was removed. The resins were washed 4 times with 1 ml of 0.2 M NaCl in 10 mM phosphate buffer to further remove unbound or poorly bound proteins. Proteins bound to DS with weak affinity were released from the resins by 0.4 M NaCl in PBS by rotating end-over-end at room temperature for 30 min, and the supernatant containing weak-binding proteins was recovered by centrifugation. The high-affinity proteins still bound to DS-resin were obtained by boiling the resins with 0.2 ml of SDS-PAGE sample buffer. Proteins in each fraction were assessed by 1D gel electrophoresis.

After the pilot assessment, fractionation of larger quantities of liver proteins was carried out by FPLC using a Biologic Duo-Flow System (Bio-Rad). Liver proteins were loaded into the DS-Sepharose column in 10 mM phosphate buffer at a rate of 1 mL/min. The column was washed with 20 mL of buffer A to remove unbound proteins. Proteins bound to DS resins with weak-to-strong affinity were eluted with a step-gradient of 0.2 M, 0.4 M, 0.6 M, and 1.0 M NaCl in 10 mM phosphate buffer, with each step being 40 ml. Elution was monitored by UV and conductivity detectors. All bound fractions were collected. Fractions were concentrated and desalted in Vivaspin centrifugal concentrators (MWCO 10 kDa, Sigma-Aldrich). Concentrated proteins were reconstituted in 10 mM phosphate buffer for further analysis.

Protein sequencing by mass spectrometry {#Sec6}
---------------------------------------

Fractionated proteins with different affinities to DS were separated on 1D SDS PAGE in 4--12% NuPAGE Novex Bis-Tris gels (Invitrogen). Based on protein band intensity, the protein lane containing proteins eluting at 0.4 M NaCl was cut into 3 sections, containing top, middle, and bottom bands. The lanes containing proteins eluting at 0.6 M and 1.0 M NaCl were each cut into 2 sections, containing top and bottom bands, respectively. Gel sections were transferred into 1-ml tubes, cut into tiny pieces, dehydrated with acetonitrile, and then dried in a speed-vac. Proteins in gel pieces were then rehydrated in 50 mM NH~4~HCO~3~ and digested with 12.5 ng/μl modified sequencing-grade trypsin (Promega) at 4 °C overnight.

Mass spectrometric sequencing was performed at the Taplin Biological Mass Spectrometry Facility (Harvard Medical School, Boston, USA). Tryptic peptides were separated on a nano-scale C18 HPLC capillary column and analyzed after electrospray ionization in an LTQ linear ion-trap mass spectrometer (Thermo Scientific). Peptide sequences and protein identities were assigned by matching protein or translated nucleotide databases with the measured fragmentation pattern using Sequest software. Peptides were required to be fully tryptic peptides with XCorr values of at least 1.5 (+ 1 ion), 1.5 (+ 2 ion), or 3.0 (+ 3 ion). All data were manually inspected. Only proteins with at least 2 peptide matches were considered confidently identified.

Results {#Sec7}
=======

Fractionation of liver proteins by DS-affinity {#Sec8}
----------------------------------------------

Proteins extracted from mouse livers were separated into 4 fractions according to their strength of binding to DS: no-, weak-, medium-, and strong-affinity. This was carried out by loading the liver proteins onto DS-Sepharose columns to allow binding to take place. Proteins that did not bind to DS resins were washed off the column with the 10 mM phosphate loading buffer, followed by washing with 0.2 M NaCl and 10 mM phosphate buffer. Afterwards, proteins that had remained bound to DS were sequentially eluted from the column with 0.4 M, 0.6 M, and 1.0 M NaCl, designating these as weak-, medium-, and strong-affinity fractions, respectively. Elution was monitored for presence of proteins, and individual chromatographic fractions containing proteins at each of the salt strengths were pooled, desalted, and concentrated. Protein content and protein size distribution of the fractions were assessed with 1D SDS PAGE gels.

The majority of liver tissue proteins not binding to DS were observed in the flow-through, and non-specific binding proteins were further washed with 0.2 M NaCl. As the elution proceeded, the amount of proteins eluting at increasing ionic strength became smaller and smaller. Proteins eluting last off the column with 1.0 M NaCl had the highest affinity to DS but were also the relatively least abundant. The flow-through and 0.2 M NaCl washed proteins were not further analyzed. Proteins eluting at 0.4 M, 0.6 M, and 1.0 M salt were sequenced by LC-MS/MS, yielding 168, 68, and 41 identified protein entities, respectively. Some of the proteins were redundantly identified in 2 or 3 fractions and, when redundancies were excluded, the number of different uniquely identified proteins in the 0.4 M, 0.6 M, or 1.0 M fraction was found to be 125, 46, and 41, respectively.

Proteins with strong DS-affinity eluting at 1.0 M ionic strength {#Sec9}
----------------------------------------------------------------

Proteins eluting off the DS-Sepharose column at 1.0 M NaCl were classified as having strong DS-affinity. From the 1.0 M elution, 41 proteins were identified by MS sequencing (Table [1](#Tab1){ref-type="table"}). A literature search revealed that at least 33 (80.5%) of these have previously been identified as autoantigens for autoantibodies. Furthermore, these autoantigens were not randomly distributed in functional attribution but fell nicely into 5 classical categories of autoantibodies in autoimmune liver diseases: ANA (antinuclear autoantibodies), SMA (smooth muscle autoantibodies), AMA (anti-mitochondrial autoantibodies), LKM (liver-kidney microsomal autoantigens), and peroxisome (Table [1](#Tab1){ref-type="table"}).Table 1Liver proteins with strong DS-affinity^a^ANA (antinuclear autoantigens)Ref.10IPI00329998.3H4Histone H4\[[@CR8]\]6IPI00114642.4Hist1h2bjHistone H2B type 1-F/J/L\[[@CR9]\]5IPI00153400.2H2afjHistone H2A.J\[[@CR9]\]5IPI00111957.3Hist1h2baHistone H2B type 1-A\[[@CR9]\]4IPI00137852.5H2afyCore histone macro-H2A.1\[[@CR10]\]2IPI00404590.1H1f0Histone H1.0\[[@CR11]\]3IPI00119220.1Snrpd2Small nuclear ribonucleoprotein Sm D2\[[@CR12]\]2IPI00114052.1SnrpbSmall nuclear ribonucleoprotein-associated protein B\[[@CR13]\]2IPI00122350.4SnrpaU1 small nuclear ribonucleoprotein A\[[@CR14]\]2IPI00133955.1SnrpeSmall nuclear ribonucleoprotein E\[[@CR15]\]3IPI00131988.1Mrpl4939S ribosomal protein L49, mitochondria\[[@CR16]\]3IPI00311236.1Rpl760S ribosomal protein L7\[[@CR17]\]2IPI00122421.5Rpl2760S ribosomal protein L27\[[@CR18]\]2IPI00222549.6Rpl3060S ribosomal protein L30\[[@CR16]\]3IPI00124287.1Pabpc1Polyadenylate-binding protein\[[@CR19]\]2IPI00119959.1Banf1Barrier-to-autointegration factor\[[@CR20]\]SMA (anti-smooth muscle autoantigens) / Cytoskeleton6IPI00753793.2Spna2Isoform 2 of Spectrin alpha chain\[[@CR21]\]5IPI00123181.4Myh9Myosin-9\[[@CR22]\]2IPI00109044.8G15RikMyosin light chain, regulatory B-like\[[@CR23]\]2IPI00354819.5Myl6Isoform Smooth muscle of Myosin light chain 6\[[@CR24]\]2IPI00230435.1LmnaIsoform C2 of Lamin-A\[[@CR25]\]AMA (anti-mitochondrial autoantigens)13IPI00319992.1Hspa578 kDa glucose-regulated protein (Grp78)\[[@CR26]\]13IPI00114209.1Glud1Glutamate dehydrogenase 1, mitochondria\[[@CR27], [@CR28]\]11IPI00131424.3Cpt2Carnitine O-palmitoyltransferase 2, mitochondria6IPI00133903.1Hspa9Stress-70 protein, mitochondria (Grp75)\[[@CR29]\]3IPI00111908.8Cps1Carbamoyl-phosphate synthase \[ammonia\], mitochondria3IPI00273146.1ChdhCholine dehydrogenase, mitochondria2IPI00129577.1Aifm1Apoptosis-inducing factor 1 (Aif, Pdcd8, programmed cell death protein 8), mitochondria\[[@CR30]\]LKM (liver-kidney microsomal autoantigens)3IPI00111936.1Ugt1a9UDP-glucuronosyltransferase 1-9 (bilirubin-specific)\[[@CR31]\]3IPI00112322.2Ugt2b5UDP glucuronosyltransferase 2 family, polypeptide B5\[[@CR32]\]2IPI00230113.5Cyb5Microsomal cytochrome b5\[[@CR33]\]2IPI00131771.3Cox6cCytochrome c oxidase subunit 6c2IPI00169666.3Ugt2b34UDP glucuronosyltransferase 2 family, polypeptide B3\[[@CR32]\]2IPI00230108.6Pdia3Protein disulfide-isomerase A\[[@CR34]\]2IPI00134746.5Ass1Argininosuccinate synthase2IPI00387289.3Ces3Carboxylesterase\[[@CR35]\]Peroxisomal proteins3IPI00112549.1Acsl1Long-chain-fatty-acid-CoA ligase2IPI00312058.5CatCatalase\[[@CR36], [@CR37]\]2IPI00223367.5UoxUricase2IPI00125325.1Decr2Peroxisomal 2,4-dienoyl-CoA reductase2IPI00125813.1Dpp4Dipeptidyl peptidase (CD26)\[[@CR38], [@CR39]\]^a^Columns left to right: Number of peptides identified for the protein by mass spectrometry; Protein ID; Gene name; Protein name; Reference (if any) reporting autoantibodies induced by the protein

Among the 41 proteins identified, 16 belong to the ANA family. They include 6 histones, 4 small nuclear ribonucleoproteins, 4 ribosomal proteins, and 2 others (polyadenylate-binding protein and barrier-to-autointegration factor). All of them are established ANA autoantigens (see references in Table [1](#Tab1){ref-type="table"}). There are 5 proteins belonging to the SMA family, including spectrin alpha chain, myosin-9, myosin light chain, and lamin-A. All of them are known targets of autoantibodies (see references in Table [1](#Tab1){ref-type="table"}). Among the AMA autoantigens, 7 were identified, with 4 having been verified as autoantigens, including Hspa5, Hspa9, glutamate dehydrogenase (Glud1), and apoptosis-inducing factor 1 (Aifm1). Autoantibodies to heat shock proteins (HSP) are widely found in autoimmune diseases as well as in numerous other diseases. Autoantibodies to HSP have been found in the circulation of various cancer patients, and are proposed as diagnostic and prognostic markers for various cancers such as breast cancer \[[@CR40]\]. Autoantibodies to Glud1 have not been reported in humans but in mice and calves \[[@CR27], [@CR28]\]. Autoantibodies to Cpt2, Cps1, and Chdh could not be found in published reports. They could well represent autoantigens that have yet to be validated.

Autoantibodies to microsomal LKM antigens are associated with type 2 autoimmune hepatitis. Among proteins with high DS-affinity, 8 microsomal proteins were identified, including 3 of the UDG-glucuronosyltransferase family, 2 cytochromes, and 3 enzymes. Six of them (Ugt1a9, Ugt2b5, UgtCyb5, Cyb5, Pdia3, and Ces3) are known bona fide autoantigens (Table [1](#Tab1){ref-type="table"}). Autoantibodies to Cox6c and Ass1 have not yet been described in literature. There are 5 proteins associated with the peroxisome in the 1.0 M elution fraction. Catalase and dipeptidyl peptidase (CD26, Dpp4) are reported autoantigens (Table [1](#Tab1){ref-type="table"}). Autoantibodies to Acsl1, Uox, and Decr2 have not yet been reported.

Proteins with moderate DS-affinity eluting at 0.6 M ionic strength {#Sec10}
------------------------------------------------------------------

From fractions eluting at 0.6 M salt from DS-affinity columns, 68 proteins were identified by MS, but 22 of them were also present in the 1.0 M fraction. Therefore, 46 unique proteins were found (Table [2](#Tab2){ref-type="table"}). Similarly to those with strong DS-affinity as described above, these proteins fell nicely into 5 categories of well-known autoantibodies: ANA, SMA, AMA, LKM, and peroxisome.Table 2Liver proteins with moderate DS-affinity^a^ANA (antinuclear autoantigens)Ref.8IPI00230730.4Hist2h3bHistone H3.2\[[@CR41]\]4IPI00223713.5Hist1h1cHistone H1.2\[[@CR42]\]2IPI00459318.1Hist1h2bpPutative uncharacterized protein, histone\[[@CR9]\]2IPI00136632.3H2afy3Histone H2A member Y3\[[@CR43]\]2IPI00320149.2H2afvHistone H2A member V\[[@CR9]\]6IPI00308706.4Rpl560S ribosomal protein L55IPI00127085.6Rpl10a60S ribosomal protein L10a3IPI00555113.2Rpl1860S ribosomal protein L183IPI00138892.2Uba52Ubiquitin-60S ribosomal protein L402IPI00122598.3EG382723Similar to ribosomal protein L105IPI00339468.4Dhx9Isoform 2 of ATP-dependent RNA helicase, DNA helicase II\[[@CR44]\]4IPI00121596.3Prpf8Pre-mRNA-processing-splicing factor 83IPI00109764.2Top1DNA topoisomerase 1 (Scl-70)\[[@CR45]\]2IPI00322749.3Snrpd1Small nuclear ribonucleoprotein Sm D1\[[@CR46]\]2IPI00120162.1Csnk2a1Casein kinase II subunit alpha\[[@CR17]\]SMA (anti-smooth muscle autoantigens) / Cytoskeleton6IPI00400300.1LmnaIsoform C of Lamin-A\[[@CR47]\]4IPI00113886.1Lmnb2Isoform B3 of Lamin-B\[[@CR48]\]2IPI00126191.5Lmnb2Isoform B2 of Lamin-B\[[@CR49]\]2IPI00113824.1Hspg2Basement membrane-specific heparan sulfate proteoglycan core protein\[[@CR50]\]AMA (anti-mitochondrial autoantigens)5IPI00331555.2BckdhaBranched chain keto acid dehydrogenase E1, alpha polypeptide (mitochondrion matrix)\[[@CR51]\]5IPI00111877.1Ssbp1Single-stranded DNA-binding protein, mitochondria4IPI00153144.3SuoxSulfite oxidase, mitochondria\[[@CR52]\]3IPI00133208.3Hspa1lHeat shock 70 kDa protein 1L\[[@CR53]\]2IPI00323357.3Hspa8Heat shock cognate 71 kDa protein\[[@CR54]\]3IPI00420718.4Hmgcs2Hydroxymethylglutaryl-CoA synthase, mitochondria\[[@CR27]\]3IPI00223092.5HadhaTrifunctional enzyme subunit alpha, mitochondria3IPI00135651.1Slc25a13Calcium-binding mitochondrial carrier protein Aralar23IPI00111885.1Uqcrc1Cytochrome b-c1 complex subunit 1, mitochondria\[[@CR33]\]3IPI00132799.4C1qbpComplement component 1 q subcomponent binding protein2IPI00127841.3Slc25a5ADP/ATP translocase (mitochondrion inner membrane)2IPI00387379.1Decr12,4-dienoyl-CoA reductase, mitochondriaLKM (liver-kidney microsomal autoantigens)6IPI00117914.3Arg1Arginase-1\[[@CR55]\]6IPI00115679.1GanabIsoform 2 of Neutral alpha-glucosidase A\[[@CR56]\]4IPI00621548.2PorNADPH-cytochrome P450 reductase\[[@CR57]\]4IPI00134691.3Ugt1a1UDP-glucuronosyltransferase 1-1\[[@CR58]\]2IPI00110556.1Cyp2e1Cytochrome P450 2E1\[[@CR59], [@CR60]\]2IPI00321644.3Cyp2d26Cytochrome P450 2D26 (mouse) (LKM1 human)\[[@CR31]\]Peroxisomal proteins6IPI00127558.3Acox1Peroxisomal acyl-coenzyme A oxidase6IPI00127276.1EhhadhEnoyl-Coenzyme A hydratase/3-hydroxyacyl CoA dehydrogenase (peroxisomal bifunctional enzyme)\[[@CR16]\]2IPI00331628.5Hsd17b4Peroxisomal multifunctional enzyme type (17 beta-hydroxysteroid dehydrogenase type 4)\[[@CR61]\]Miscellaneous4IPI00115599.6Hsd11b1Corticosteroid 11-beta-dehydrogenase isozyme3IPI00117705.1DdostDolichyl-diphosphooligosaccharide-protein glycosyltransferase 48 kDa subunit3IPI00313236.3Slc27a5Bile acyl-CoA synthetase2IPI00309035.2Rpn1Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit 1 (ribophorin 1)2IPI00127016.1Hsd17b6Hydroxysteroid 17-beta dehydrogenase\[[@CR62]\]2IPI00130985.1Rdh7Retinol dehydrogenase^a^Columns left to right: Number of peptides identified for the protein by mass spectrometry; Protein ID; Gene name; Protein name; Reference (if any) reporting autoantibodies induced by the protein

There are 15 proteins belonging to the ANA family, including 5 histones and 5 ribosomal proteins (Table [2](#Tab2){ref-type="table"}). Aside from these, other interesting autoantigens were identified. DNA topisomerase 1, the classical Scl-70 autoantigen, was identified \[[@CR45]\]. Casein kinase II was also identified \[[@CR17]\]. Dxh9 (ATP-dependent RNA helicase and DNA helicase II) may resemble the classical Ku antigen \[[@CR44]\]. Prpf8, a pre-mRNA-processing-splicing factor, has not been reported as an autoantigen.

There are 4 proteins belonging to the SMA family. Aside from 3 isoforms of lamin, autoantigen Hspg2 (basement membrane-specific heparan sulfate proteoglycan core protein) was found in the 0.6 M elution. Among the 12 proteins in the AMA family, autoantibodies to 6 have been reported, including Bckdha, Suox, Hspa1l, Hmgcs2, Uqcrc1, and Hspa8. Although autoantibodies to C1q have been widely studied, anti-C1qbp (complement C1q subunit binding protein) has not yet been reported. Ssbp1, Hadha, Scl25a5, or Decr1 were not found in the literature as autoantigens.

From the 0.6 M elution, all 6 proteins identified in the LKM family are reported autoantigens (see references in Table [2](#Tab2){ref-type="table"}). The classical cytochrome P450 antigens including LKM1 were identified. Other autoantigens identified are UDP-glucuronosyltransferase 1, Arg1, and Ganab. In addition to the above classical categories of autoantigens, 6 proteins identified in the 0.6 M elution are miscellaneous. Except for Rdh7 being a reported autoantigen, Hsd11b1, Ddost, Slc27a5, Rpn1, and Hsd17b6 autoantibodies remain to be characterized.

Proteins with weak DS-affinity eluting at 0.4 M ionic strength {#Sec11}
--------------------------------------------------------------

From fractions eluting at 0.4 M salt, 168 proteins were initially identified. Among these, 18 were also found in both 0.6 M and 1.0 M elution, including H2bj, H2afj, H2afy, Snrpb, Myh9, Lmna, Hspa9, Hspa5, Cps1, Cpt2, Glud1, Ugt2b5, Pdia3, Ass1, Acsl1, Cat, Uox, and Aif. Among the rest, 3 (Sm D2, Spna2, and Ces) were found also in the 1.0 M elution but in not 0.6 M elution, and 22 proteins were found also in the 0.6 M but not in the 1.0 M elution. After excluding these redundancies, 125 proteins were found only in the 0.4 M elution (Table [3](#Tab3){ref-type="table"}).Table 3Liver proteins with weak DS-affinity^a^ANA (antinuclear autoantigens)Ref.19IPI00122011.2Sf3b3Isoform 1 of Splicing factor 3B subunit\[[@CR63]\]14IPI00420807.3Sfrs1Isoform 1 of Splicing factor, arginine/serine-rich2IPI00153743.1Sfrs7Isoform 2 of Splicing factor, arginine/serine-rich4IPI00123604.4Rpsa40S ribosomal protein SA3IPI00469260.3Eftud2116 kDa U5 small nuclear ribonucleoprotein component\[[@CR64]\]2IPI00170008.1Snrpa1U2 small nuclear ribonucleoprotein A\[[@CR65]\]2IPI00114052.1SnrpbSmall nuclear ribonucleoprotein-associated protein\[[@CR13]\]2IPI00119220.1Snrpd2Small nuclear ribonucleoprotein Sm D2\[[@CR66]\]2IPI00226073.2HnrnpfIsoform 1 of Heterogeneous nuclear ribonucleoprotein F2IPI00109860.3Rbm8aIsoform 2 of RNA-binding protein 8SMA (anti-smooth muscle autoantigens)/Cytoskeleton19IPI00123316.1Tpm1Isoform 1 of Tropomyosin alpha-1 chain\[[@CR67]\]13IPI00169707.2Tpm3Tropomyosin 3, gamm\[[@CR68]\]9IPI00230044.5Tpm3Isoform 2 of Tropomyosin alpha-3 chain2IPI00421223.3Tpm4Tropomyosin alpha-4 chain\[[@CR69]\]13IPI00118899.1Actn4Alpha-actinin\[[@CR70]\]9IPI00113539.2Fn1Fibronectin\[[@CR71]\]7IPI00110850.1ActbActin, cytoplasmic\[[@CR72]\]6IPI00110827.1Acta1Actin, alpha skeletal muscle\[[@CR72]\]7IPI00265380.4Myh8Myosin-8\[[@CR73]\]3IPI00129404.1Myh6Myosin-63IPI00114894.1Myh11Isoform 1 of Myosin-15IPI00230394.5Lmnb1Lamin-B\[[@CR74]\]4IPI00121892.9Spnb2Isoform 2 of Spectrin beta chain\[[@CR75]\]3IPI00227299.6VimVimentin\[[@CR69]\]2IPI00109061.1Tubb2bTubulin beta-2B chain\[[@CR76]\]AMA (anti-mitochondrial autoantigens)52IPI00129526.1Hsp90b1Endoplasmin\[[@CR26]\]9IPI00229080.7Hsp90ab1MCG18234IPI00330804.4Hsp90aa1Heat shock protein HSP 90-alpha39IPI00136213.5SardhSarcosine dehydrogenase, mitochondrial31IPI00468481.2Atp5bATP synthase subunit beta, mitochondrial\[[@CR77]\]21IPI00130280.1Atp5a1ATP synthase subunit alpha, mitochondrial27IPI00471246.2IvdIsovaleryl-CoA dehydrogenase, mitochondrial17IPI00134809.2DlstIsoform 1 of Dihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrial\[[@CR78]\]2IPI00756386.1Dhtkd1Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1, mitochondrial13IPI00331564.2DldDihydrolipoyl dehydrogenase7IPI00130535.1DbtLipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial\[[@CR78]\]3IPI00153660.4DlatDihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial13IPI00387491.1AassAlpha-aminoadipic semialdehyde synthase, mitochondrial13IPI00468653.4PccbPropionyl-CoA carboxylase beta chain, mitochondrial12IPI00330523.1PccaPropionyl-CoA carboxylase alpha chain, mitochondrial11IPI00110843.3AgmatAgmatinase, mitochondrial9IPI00114710.2PcxPyruvate carboxylase, mitochondrial isoform 27IPI00111218.1Aldh2Aldehyde dehydrogenase, mitochondrial\[[@CR27]\]4IPI00226430.2Acaa23-Ketoacyl-CoA thiolase, mitochondrial3IPI00119766.1Rdh16Retinol dehydrogenase 13IPI00405699.2Aldh4a1Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial3IPI00121309.2Ndufs3NADH dehydrogenase \[ubiquinone\] iron-sulfur protein 3, mitochondrial3IPI00753303.2Npl22Dihydrodipicolinate synthase-like, mitochondrial3IPI00169862.1Coq9Ubiquinone biosynthesis protein COQ9, mitochondrial2IPI00323592.2Mdh2Malate dehydrogenase, mitochondrial2IPI00121105.2HadhHydroxyacyl-coenzyme A dehydrogenase, mitochondrial2IPI00459725.2Idh3aIsoform 1 of Isocitrate dehydrogenase \[NAD\] subunit alpha, mitochondrial\[[@CR79]\]2IPI00133553.1MutMethylmalonyl-CoA mutase, mitochondrial2IPI00115607.3HadhbTrifunctional enzyme subunit beta, mitochondrial2IPI00130804.1Ech1Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial\[[@CR80]\]2IPI00469195.2Echdc2Isoform 1 of Enoyl-CoA hydratase domain-containing protein 2, mitochondrial2IPI00314909.2AgxtAlanine-glyoxylate aminotransferase2IPI00226140.5MaobAmine oxidase \[flavin-containing\]\[[@CR81]\]2IPI00121440.4EtfbElectron transfer flavoprotein subunit beta\[[@CR82]\]2IPI00454008.1Shmt2Serine hydroxymethyltransferaseLKM (liver-kidney microsomal autoantigens)54IPI00309073.2MttpMicrosomal triglyceride transfer protein33IPI00153317.3Aldh1l110-formyltetrahydrofolate dehydrogenase10IPI00111936.1Ugt1a9UDP-glucuronosyltransferase 1-9\[[@CR31]\]8IPI00762897.2Ugcgl1UDP-glucose:glycoprotein glucosyltransferase3IPI00127223.3Ugt2b36UDP-glucuronosyltransferase3IPI00114778.1Cyp2c37Cytochrome P450 2C37\[[@CR83]\]3IPI00131176.1mt-Co2Cytochrome c oxidase subunit 22IPI00323908.1Cyp2d10Cytochrome P450 2D10\[[@CR83]\]3IPI00331322.3Mgst1Microsomal glutathione S-transferase9IPI00115867.4Ces1Liver carboxylesterase\[[@CR35]\]Peroxisomal proteins6IPI00331596.6PecrPeroxisomal trans-2-enoyl-CoA reductase3IPI00134870.3Acox2Peroxisomal acyl-coenzyme A oxidase5IPI00110719.1PipoxPeroxisomal sarcosine oxidase\[[@CR84]\]2IPI00130924.1Slc27a2Very long-chain acyl-CoA synthetaselow-den2IPI00121833.3Acaa1aAcaa1b 3-ketoacyl-CoA thiolase A, peroxisomal2IPI00111235.2Aldh3a2Fatty aldehyde dehydrogenase variantApoptosis9IPI00310240.4Anxa6Annexin A6 isoform\[[@CR85]\]5IPI00116498.1Ywhaz14-3-3 protein zeta/delta\[[@CR86]\]5IPI00118384.1Ywhae14-3-3 protein epsilon\[[@CR87]\]5IPI00230707.6Ywhag14-3-3 protein gamma\[[@CR87]\]Proteasome8IPI00113845.1Psmb1Proteasome subunit beta type-1\[[@CR88]\]4IPI00119239.2Psmb6Proteasome subunit beta type-63IPI00116712.1Psmb8Proteasome subunit beta type-82IPI00128945.1Psmb2Proteasome subunit beta type-22IPI00129512.3Psmb4Proteasome subunit beta type-42IPI00136483.1Psmb7Proteasome subunit beta type-75IPI00331644.5Psma3Proteasome subunit alpha type-3\[[@CR88]\]4IPI00109122.1Psma8Proteasome subunit alpha type-7-like4IPI00131845.1Psma6Proteasome subunit alpha type-64IPI00420745.7Psma2Proteasome subunit alpha type-24IPI00277001.4Psma4Proteasome subunit alpha type-4\[[@CR89]\]Miscellaneous68IPI00123639.1CalrCalreticulin\[[@CR77]\]67IPI00271951.5Pdia4Protein disulfide isomerase A61IPI00122815.3P4hbProtein disulfide-isomerase\[[@CR90]\]17IPI00222496.3Pdia6Putative uncharacterized protein2IPI00163011.2Txndc5Thioredoxin domain-containing protein20IPI00119618.1CanxCalnexin\[[@CR91]\]18IPI00622235.5VcpTransitional endoplasmic reticulum ATPase\[[@CR92]\]14IPI00125514.1Entpd5Ectonucleoside triphosphate diphosphohydrolase 511IPI00475154.1Rpn2Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit2IPI00309035.2Rpn1Dolichyl-diphosphooligosaccharide\--protein glycosyltransferase subunit11IPI00112719.1AladDelta-aminolevulinic acid dehydratase10IPI00115680.1PrkcshIsoform 1 of Glucosidase 2 subunit beta7IPI00119063.2Lrp1Pro-low-density lipoprotein receptor-related protein (alpha-2-macroglobulin receptor, apolipoprotein E receptor)2IPI00624663.3PzpAlpha-2-macroglobulin7IPI00135512.1Cnpy2Protein canopy homolog 26IPI00316314.1Hacl12-hydroxyacyl-CoA lyase6IPI00116254.1Prdx4Peroxiredoxin-4\[[@CR93]\]6IPI00125899.1Ctnnb1Catenin beta-14IPI00112963.1Ctnna1Catenin alpha-1\[[@CR94]\]5IPI00113869.1BsgIsoform 2 of Basigin (M6, EMMPRIN, TCSF, CD147)4IPI00126184.7GcVitamin D-binding protein\[[@CR95]\]4IPI00123342.4Hyou1Hypoxia up-regulated protein3IPI00130950.1BhmtBetaine\--homocysteine S-methyltransferase\[[@CR96]\]3IPI00134058.3Erp44Endoplasmic reticulum resident protein ERp443IPI00387282.4AadacArylacetamide deacetylase3IPI00122346.2Ssr4Signal sequence receptor, delta3IPI00317740.5Gnb2l1Guanine nucleotide-binding protein subunit beta-2-like3IPI00319973.3Pgrmc1Membrane-associated progesterone receptor component2IPI00279218.1ApehIsoform 2 of Acylamino-acid-releasing enzyme2IPI00323624.3C3Isoform Long of Complement C3\[[@CR97]\]2IPI00116432.1Fmo1Dimethylaniline monooxygenase \[N-oxide-forming\]2IPI00114044.1Man2a1Alpha-mannosidase2IPI00312018.6MlecMalectin2IPI00115241.1Mup4Major urinary protein 4^a^Columns left to right: Number of peptides identified for the protein by mass spectrometry; Protein ID; Gene name; Protein name; Reference (if any) reporting autoantibodies induced by the protein

As shown in Table [3](#Tab3){ref-type="table"}, these 125 proteins fell naturally into 8 categories: ANA (10 proteins), SMA (15 proteins), AMA (35 proteins), LKM (10 proteins), peroxisome (6 proteins), apoptosis (4 proteins), proteasome (11 proteins), and miscellaneous (34 proteins).

The ANA autoantigens with weak DS-affinity are primarily isoforms of splicing factors and small nuclear ribonucleoproteins. Although autoantibodies to splicing factors have been reported \[[@CR63]\], the exact isoforms identified here have not been reported. Anti-smooth muscle autoantigens identified in the 0.4 M NaCl elution included various forms of tropomyosin, actinin, fibronectin, actin, myosin, lamin, spectrin, and tubulin. Among the 15 identified here, 12 are bona fide autoantigens. Among the 35 proteins associated with mitochondria, 32 are enzymes, with 8/32 being reported autoantigens. These enzymes are from diverse families, e.g., dehydrogenases, synthases, acyltransferases, or carboxylases.

Similar to those identified in the 1.0 M and 0.6 M factions, the LKM autoantigens included members of cytochrome and UDP-glucuronosyltransferase families. In addition, 3 unrelated proteins, Mttp, Aldh1l1, and Ces1 were identified. Ces1 is a verified autoantigen. Six enzymes associated with the peroxisome were identified. Thus far, only peroxisomal sarcosine oxidase has been described to be an autoantigen. In addition to the above autoantigen categories, additional proteins were found associated with apoptosis and the proteasome (Table [3](#Tab3){ref-type="table"}). Annexin A6 and 14--3-3 proteins are reported autoantigens. Members of the proteasome have also been reported as autoantigens.

The remaining 34 proteins could not easily be classified into particular categories. The majority of them are not yet characterized as autoantigens. However, some are reported autoantigens, such as calreticulin, calnexin, catenin, protein disulfide-isomerase, peroxiredoxin 4, vitamin D-binding protein, and complement C3 (Table [3](#Tab3){ref-type="table"}).

Discussion {#Sec12}
==========

Under normal physiologic conditions, the immune system is designed to protect from infection and disease through intricate mechanisms that distinguish self from non-self. It is a mystery why and how the immune system is mistakenly triggered to attack the body's self. Autoimmune responses are causally linked to autoantibodies, autoreactive cells, or both. Despite advances in our understanding of the many facets of autoimmunity, the underlying molecular and cellular mechanisms that trigger autoimmunity remain largely unknown.

We are intrigued by the question why and how a vast number of diverse, seemingly functionally disconnected proteins in different parts of the body and with diverse structures and biological functions can all induce a converging autoimmune response, i.e., the production of autoantibodies by autoreactive B cells. Based on our previous studies \[[@CR1], [@CR2]\], we concluded that autoantigens share a common biochemical property in their binding affinity to dermatan sulfate (DS), also called chondroitin sulfate B, a glycosaminoglycan-type mucopolysaccharide found mostly in skin but also in blood vessels, heart valves, tendons, lungs, and other tissues. DS can directly bind molecules released from dying cells or other sources and form macromolecular DS-autoantigen complexes, and such complexes, in turn, can stimulate autoreactive B cells through simultaneous engagement of multiple signaling molecules on the B cell surface to induce an activated B cell response. To further characterize our proposed "unifying principle of autoantigenicity" based on DS-affinity as a shared physicochemical property of autoantigens, we tested whether we could identify autoantigens from a specific parenchymal organ, and whether autoantigens showed preferential intrinsic biochemical propensity for high DS-affinity.

Autoimmune liver diseases result from the immune system mistakenly attacking hepatocytes or cholangiocytes in the liver \[[@CR3]--[@CR5]\]. Patients with these chronic conditions are usually initially rather asymptomatic, and autoantibody serology tests are often necessary to clarify the diagnosis \[[@CR6], [@CR7]\]. For example, while routine blood tests for liver enzymes can reveal patterns of hepatitis, further autoantibody tests are needed to diagnose autoimmune hepatitis. Autoantibody tests also help distinguish autoimmune hepatitis from other liver diseases, such as viral hepatitis or metabolic diseases such as Wilson disease.

Common autoimmune liver diseases include autoimmune hepatitis (AIH) \[[@CR3]\], primary biliary cirrhosis (PBC) \[[@CR4]\], and primary sclerosing cholangitis (PSC) \[[@CR5]\]. An autoimmune liver disease panel (a series of tests that detect autoantibodies to common autoantigens associated with these diseases) include anti-liver-kidney microsomal antibodies (LKM), anti-mitochondrial antibodies (AMA), anti-nuclear antibodies (ANA), and anti-smooth muscle antibodies (SMA). AIH is further classified to two types, type I is defined by positive ANA and SMA, whereas type 2 is associated with anti-KLM autoantibodies. ANA occur in a wide variety of systemic autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Sjögren syndrome, and systemic sclerosis. Lupus hepatitis is regarded as a distinct manifestation of SLE \[[@CR98]\]. The identification of 41 confirmed or putative ANA autoantigens from liver tissue uncovered by our study may perhaps explain the overlap autoantibody profile and clinical manifestations between lupus and AIH. AMA are hallmark diagnostic markers for PBC. In PBC, the targets are small bile ducts, but the prototypic serologic response is the production of a multilineage immune response to mitochondrial autoantigens. AMA are detected in 90--95% of PBC patients, although their presence is extremely low in the general population (varying between 0.16 and 1%) \[[@CR99]\]. More than 60 autoantibodies have been detected in patients with PBC \[[@CR99]\]. In our current study, we identified 54 verified and putative autoantigens associated with mitochondria.

Based on all of our observation so far, we find that autoantigens with the strongest DS affinity are typically DNA- and RNA-binding proteins. Other autoantigens largely display moderate to weak DS affinity. However, it should be noted that our definition of DS binding strength is arbitrary, with DS-autoAg complexes dissociable at 1.0, 0.6, and 0.4 M ionic strength defined as strongly, moderately, and weakly binding, respectively. All of these DS-binding proteins would be expected to remain in complexed forms with DS under physiologic conditions. For example, cytochrome P450 2D6 (CYP2D6) is the major autoantigen of LKM1 autoantibodies \[[@CR100]\], but its mouse homologues (Cyp2d26 and Cyp2d10) were found to possess only moderate to weak DS affinity (Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}). As another example, PDC-E2 is a major autoantigen in PBC patients, but several components of the PDC (pyruvate dehydrogenase complex) were only identified in the weak but not the strong DS affinity fraction of this study (Table [3](#Tab3){ref-type="table"}). Hence, these results suggest that proteins only need to exhibit some (sufficient) DS affinity to become potentially autoantigenic. It is also possible that in toto weakly DS-binding proteins may contain fragment epitopes with strong DS affinity, and such epitopes could determine the autoantigenicity of the protein.

The liver is the largest internal organ, the largest gland of the human body, and also the largest reservoir of human proteins. The liver serves hundreds of physiological functions, including removal of toxic substance, storage of glycogen, decomposition of red blood cells, production of bile and hormones, and synthesis of plasma proteins. Transcriptome analysis shows that 59% (*n* = 11,553) of all human proteins (*n* = 19,613) are expressed in the liver (The Human Protein Atlas). It should be noted that our DS-affinity approach provided a significant enrichment of liver protein autoantigens, yielding only a little over 200 proteins (i.e., around 1% of the total human proteome) as bona fide verified or potential autoantigens.

Conclusions {#Sec13}
===========

Our study of DS-affinity enrichment of the liver proteome produced a comprehensive autoantigen-ome that includes 104 bona fide autoantigens and 108 potential autoantigens for autoimmune liver diseases. These autoantigens fell into the classical categories of autoantibodies for autoimmune liver diseases. Our study provides further support to a model in which DS-affinity is a distinct biochemical property of proteins that can become autoantigens, whereas proteins that lack DS-affinity have a much lower propensity to be targets of autoimmunity (Fig. [1](#Fig1){ref-type="fig"}). These results may help in the further characterization of autoantigenic molecules and thus point to new innovative directions in autoimmunity research.Fig. 1Model illustrating our hypothesis that binding affinity to dermatan sulfate is a distinct biochemical property characterizing (a small subset of) human proteins (estimated at \~ 1%) that can become human autoantigens, whereas the majority of proteins (estimated at \~ 99%) that lack binding affinity have a much lower propensity to become targets of autoimmunity
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